Clinical trials: CRC, Colorectal Cancer
Advanced Cancers
Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer
The goal of this clinical research study is to learn if Lipitor (atorvastatin) or fish oil supplements can help to control side effects of the heart that are commonly seen after lung surgery (such as irregular heartbeat).
- Trial name
- NCT01259284
- Testing
- Atorvastatin, Fish Oil Supplement
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
RATIONALE: Chemoprotective drugs, such as calcium gluconate and magnesium sulfate, may prevent neurotoxicity caused by oxaliplatin.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
- Trial name
- NCT01099449
- Testing
- calcium gluconate, magnesium sulfate, oxaliplatin
- Where
- 405 sites in United States, Puerto Rico
- Volunteers
- 362 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer Metastatic, Myelosuppression-Adult
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in…
- Conditions
- Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
- Trial name
- PRESERVE1 (NCT04607668)
- Testing
- Trilaciclib
- Where
- 82 sites in United States, China and 6 more
- Volunteers
- 326 people
- Sponsor
- G1 Therapeutics, Inc.
Metastatic Colorectal Cancer
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
- Trial name
- NCT02981524
- Testing
- CY, GVAX, Pembrolizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Metastatic (Stage IV) Colorectal Cancer
A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
The present trial is designed to determine whether pre-treatment with PledOx lowers the frequency and severity of side effects from FOLFOX6 administration in patients with metastatic colorectal cancer.
- Trial name
- PLIANT (NCT01619423)
- Testing
- PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg)
- Where
- 33 sites in United States, Bulgaria and 6 more
- Volunteers
- 186 people
- Sponsor
- Egetis Therapeutics AB (publ)
BRAF V600E, Metastatic Colorectal Cancer
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic…
- Trial name
- NAUTICALCRC (NCT05004350)
- Testing
- Encorafenib, Cetuximab, FOLFIRI
- Where
- 34 sites in China
- Volunteers
- 107 people
- Sponsor
- Pierre Fabre Medicament
Colorectal Cancer, Metastases
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after…
- Trial name
- NCT00089635
- Testing
- Panitumumab
- Volunteers
- 203 people
- Sponsor
- Amgen
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03642067
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.
- Trial name
- NCT01694966
- Testing
- Methylene Blue MMX®
- Where
- 19 sites in United States, Belgium and 6 more
- Volunteers
- 1,249 people, healthy volunteers welcome
- Sponsor
- Cosmo Technologies Ltd
Colorectal Cancer, Colorectal Neoplasms
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Background: T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT02298946
- Testing
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening
Shared decision-making (SDM) has been advocated as a strategy for increasing colorectal cancer (CRC) screening rates. Our studies to date suggest that while the use of a novel computer-based decision aid facilitates several…
- Trial name
- NCT01596582
- Testing
- Risk Assessment
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Metastatic Colorectal Cancer
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to…
- Trial name
- NCT02448810
- Testing
- BAX69 + infusional 5-FU/LV, BAX69 + panitumumab, BAX69 + 5-FU/LV
- Where
- 12 sites in United States
- Volunteers
- 115 people
- Sponsor
- Baxalta now part of Shire
Colorectal Cancer
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
- Trial name
- RECOURSE (NCT01607957)
- Testing
- TAS-102
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 800 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Colorectal Cancer
Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
The purpose of this study is to find out what effects, good and/or bad, MEDI4736 has on the patient and cancer. MEDI4736 is a type of medication called an antibody.
- Trial name
- NCT02227667
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Neoplasms, Neoplasm Metastasis
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan…
- Trial name
- VELOUR (NCT00561470)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- Where
- 221 sites in United States, Argentina and 26 more
- Volunteers
- 1,226 people
- Sponsor
- Sanofi
Colo-rectal Cancer
A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with…
- Trial name
- AGENT (NCT03750786)
- Testing
- Arfolitixorin, Leucovorin
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 490 people
- Sponsor
- Isofol Medical AB
Colorectal Cancer
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
This 2 arm study will compare the safety and efficacy of oral Xeloda, or 5-fluorouracil in combination with leucovorin, in patients who have undergone surgery for colon cancer.
- Trial name
- NCT00009737
- Testing
- 5-Fluorouracil, Leucovorin, Capecitabine [Xeloda]
- Where
- 133 sites in United States, Argentina and 12 more
- Volunteers
- 1,987 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Colon Cancer, Rectal Cancer
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
The purpose of this study is to test a new drug called MK-2206 for metastatic colorectal cancer. This drug is being tested in a subgroup of patients with colorectal cancer whose tumors have changes in certain genes that may make…
- Trial name
- NCT01186705
- Testing
- MK-2206
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center